Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., announced the publication of exploratory Phase 2 clinical trial results for its core product, Tiengogatinib, targeting cholangiocarcinoma in the journal "The Lancet Gastroenterology & Hepatology" [1] Group 1: Clinical Trial Details - The Phase 2 study (NCT04919642) is an open-label, multicenter trial involving eligible cholangiocarcinoma patients, including those with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - Tiengogatinib demonstrates the ability to overcome acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma patients and shows antitumor activity in patients with other FGFR gene alterations [1] Group 2: Disease Background - Cholangiocarcinoma is a highly aggressive cancer of the biliary system, often driven by FGFR2 fusions, which can be targeted by inhibitors such as pemigatinib and futibatinib [1] - The emergence of acquired FGFR2 mutations frequently leads to resistance against these targeted therapies [1]

Core Viewpoint - The company, Zai Lab Limited, announced the publication of exploratory Phase 2 clinical trial results for its core product, Tzenglongtinib, targeting cholangiocarcinoma in a high-impact medical journal [1] Group 1: Clinical Trial Details - The Phase 2 study (NCT04919642) is an open-label, multicenter trial involving eligible cholangiocarcinoma patients with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - The study also includes patients with other FGFR gene alterations and those with wild-type FGFR [1] Group 2: Drug Efficacy - Tzenglongtinib demonstrates the ability to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma [1] - The drug shows anti-tumor activity in cholangiocarcinoma patients with other FGFR gene alterations [1]

Core Insights - The core product of the company, Tiengotine, has shown promising results in a Phase 2 exploratory clinical trial for cholangiocarcinoma published in The Lancet Gastroenterology & Hepatology [1] Company Summary - Tiengotine is designed to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma, demonstrating anti-tumor activity in patients with other FGFR gene alterations and FGFR wild-type patients [1]